There were no differences among the FCGs in the rates of change or choice of new antipsychotic drug. One or more doses of low-potency first-generation antipsychotics were given to 15 patients (15.8%).

Risperidone was also tested in comparison with various augmentation agents in a recent RCT, 225 TRD patients were randomly assigned to receive an 8-week treatment of paroxetine 20 mg/day augmented ...